Search Results

Summary This MAb is directed against the peptide core and reacts with both the plasma and cellular forms of fibronectin. It blocks the fibronectin-medicated cell attachment not by disrupting the collagen-fibronectin interaction, but by interfering with the attachment of fibronectin to its receptor on the cell surface.